Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial

Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial Publisher Pubmed

Bikdeli B^{1, 2, 3} ; Talasaz AH⁴ ; Rashidi F⁵ ; Bakhshandeh H^{6, 7} ; Rafiee F⁷ ; Rezaeifar P⁵ ; Baghizadeh E⁷ ; Matin S⁵ ; Jamalkhani S⁸ ; Tahamtan O⁵ ; Sharifkashani B^{9, 10} ; Beigmohammadi MT¹¹ ; Farrokhpour M¹² ; Sezavar SH¹³ Show All Authors

Bikdeli B^{1, 2, 3}
Talasaz AH⁴
Rashidi F⁵
Bakhshandeh H^{6, 7}
Rafiee F⁷
Rezaeifar P⁵
Baghizadeh E⁷
Matin S⁵
Jamalkhani S⁸
Tahamtan O⁵
Sharifkashani B^{9, 10}
Beigmohammadi MT¹¹
Farrokhpour M¹²
Sezavar SH¹³
Payandemehr P¹⁴
Dabbagh A¹⁵
Moghadam KG¹⁶
Khalili H¹⁷
Yadollahzadeh M¹²
Riahi T¹⁸
Abedini A¹⁹
Lookzadeh S¹⁹
Rahmani H²⁰
Zoghi E²¹
Mohammadi K²¹
Sadeghipour P¹²
Abri H¹²
Tabrizi S¹⁸
Mousavian SM¹⁸
Shahmirzaei S¹⁴
Amin A⁷
Mohebbi B²²
Parhizgar SE⁷
Aliannejad R^{23, 24}
Eslami V²⁵
Kashefizadeh A²⁶
Dobesh PP²⁷
Kakavand H²¹
Hosseini SH²¹
Shafaghi S¹⁰
Ghazi SF¹¹
Najafi A¹⁴
Jimenez D^{28, 29, 30}
Gupta A^{2, 3, 31}
Madhavan MV^{3, 31}
Sethi SS^{3, 31}
Parikh SA^{3, 31}
Monreal M^{32, 33}
Hadavand N⁷
Hajighasemi A⁴
Maleki M⁷
Sadeghian S⁴
Piazza G¹
Kirtane AJ^{3, 31}
Van Tassell BW^{34, 35}
Stone GW^{3, 36}
Lip GYH^{37, 38}
Krumholz HM^{2, 39, 40}
Goldhaber SZ¹
Sadeghipour P¹²

Source: Thrombosis and Haemostasis Published:2021

Abstract

Background Thrombotic complications are considered among the main extrapulmonary manifestations of coronavirus disease 2019 (COVID-19). The optimal type and duration of prophylactic antithrombotic therapy in these patients remain unknown. Methods This article reports the final (90-day) results of the Intermediate versus Standard-dose Prophylactic anticoagulation In cRitically-ill pATIents with COVID-19: An opeN label randomized controlled trial (INSPIRATION) study. Patients with COVID-19 admitted to intensive care were randomized to intermediate-dose versus standard-dose prophylactic anticoagulation for 30 days, irrespective of hospital discharge status. The primary efficacy outcome was a composite of adjudicated venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation (ECMO), or all-cause death. The main safety outcome was major bleeding. Results Of 600 randomized patients, 562 entered the modified intention-to-treat analysis (median age [Q1, Q3]: 62 [50, 71] years; 237 [42.2%] women), of whom 336 (59.8%) survived to hospital discharge. The primary outcome occurred in 132 (47.8%) of patients assigned to intermediate dose and 130 (45.4%) patients assigned to standard-dose prophylactic anticoagulation (hazard ratio [HR]: 1.21, 95% confidence interval [CI]: 0.95-1.55, p = 0.11). Findings were similar for other efficacy outcomes, and in the landmark analysis from days 31 to 90 (HR: 1.59, 95% CI: 0.45-5.06). There were 7 (2.5%) major bleeding events in the intermediate-dose group (including 3 fatal events) and 4 (1.4%) major bleeding events in the standard-dose group (none fatal) (HR: 1.82, 95% CI: 0.53-6.24). Conclusion Intermediate-dose compared with standard-dose prophylactic anticoagulation did not reduce a composite of death, treatment with ECMO, or venous or arterial thrombosis at 90-day follow-up. © 2021. Thieme. All rights reserved.

Related Docs

View other Related Docs

1. Effect of Intermediate-Dose Vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With Covid-19 Admitted to the Intensive Care Unit: The Inspiration Randomized Clinical Trial, JAMA - Journal of the American Medical Association (2021)

2. Recent Randomized Trials of Antithrombotic Therapy for Patients With Covid-19: Jacc State-Of-The-Art Review, Journal of the American College of Cardiology (2021)

3. Covid-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment, Seminars in Thrombosis and Hemostasis (2023)

Experts (# of related papers)

View all Related Experts

Azita Hajhossein Talasaz (11)

Mohammad Taghi Beigmohammadi (5)

Style	Citing Format
MLA	Bikdeli B, et al.. "Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial." Thrombosis and Haemostasis, vol. 122, no. 1, 2021, pp. 131-141.
APA	Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Rezaeifar P, Baghizadeh E, Matin S, Jamalkhani S, Tahamtan O, Sharifkashani B, Beigmohammadi MT, Farrokhpour M, Sezavar SH, Payandemehr P, Dabbagh A, Moghadam KG, Khalili H, Yadollahzadeh M, ... Sadeghipour P (2021). Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial. Thrombosis and Haemostasis, 122(1), 131-141.
Chicago	Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Rezaeifar P, Baghizadeh E, et al.. "Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial." Thrombosis and Haemostasis 122, no. 1 (2021): 131-141.
Harvard	Bikdeli B et al. (2021) 'Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial', Thrombosis and Haemostasis, 122(1), pp. 131-141.
Vancouver	Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Rezaeifar P, et al.. Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial. Thrombosis and Haemostasis. 2021;122(1):131-141.
BibTex	@article{ author = {Bikdeli B and Talasaz AH and Rashidi F and Bakhshandeh H and Rafiee F and Rezaeifar P and Baghizadeh E and Matin S and Jamalkhani S and Tahamtan O and Sharifkashani B and Beigmohammadi MT and Farrokhpour M and Sezavar SH and Payandemehr P and Dabbagh A and Moghadam KG and Khalili H and Yadollahzadeh M and Riahi T and Abedini A and Lookzadeh S and Rahmani H and Zoghi E and Mohammadi K and Sadeghipour P and Abri H and Tabrizi S and Mousavian SM and Shahmirzaei S and Amin A and Mohebbi B and Parhizgar SE and Aliannejad R and Eslami V and Kashefizadeh A and Dobesh PP and Kakavand H and Hosseini SH and Shafaghi S and Ghazi SF and Najafi A and Jimenez D and Gupta A and Madhavan MV and Sethi SS and Parikh SA and Monreal M and Hadavand N and Hajighasemi A and Maleki M and Sadeghian S and Piazza G and Kirtane AJ and Van Tassell BW and Stone GW and Lip GYH and Krumholz HM and Goldhaber SZ and Sadeghipour P}, title = {Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial}, journal = {Thrombosis and Haemostasis}, volume = {122}, number = {1}, pages = {131-141}, year = {2021} }
RIS	TY - JOUR AU - Bikdeli B AU - Talasaz AH AU - Rashidi F AU - Bakhshandeh H AU - Rafiee F AU - Rezaeifar P AU - Baghizadeh E AU - Matin S AU - Jamalkhani S AU - Tahamtan O AU - Sharifkashani B AU - Beigmohammadi MT AU - Farrokhpour M AU - Sezavar SH AU - Payandemehr P AU - Dabbagh A AU - Moghadam KG AU - Khalili H AU - Yadollahzadeh M AU - Riahi T AU - Abedini A AU - Lookzadeh S AU - Rahmani H AU - Zoghi E AU - Mohammadi K AU - Sadeghipour P AU - Abri H AU - Tabrizi S AU - Mousavian SM AU - Shahmirzaei S AU - Amin A AU - Mohebbi B AU - Parhizgar SE AU - Aliannejad R AU - Eslami V AU - Kashefizadeh A AU - Dobesh PP AU - Kakavand H AU - Hosseini SH AU - Shafaghi S AU - Ghazi SF AU - Najafi A AU - Jimenez D AU - Gupta A AU - Madhavan MV AU - Sethi SS AU - Parikh SA AU - Monreal M AU - Hadavand N AU - Hajighasemi A AU - Maleki M AU - Sadeghian S AU - Piazza G AU - Kirtane AJ AU - Van Tassell BW AU - Stone GW AU - Lip GYH AU - Krumholz HM AU - Goldhaber SZ AU - Sadeghipour P TI - Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial JO - Thrombosis and Haemostasis VL - 122 IS - 1 SP - 131 EP - 141 PY - 2021 ER -

Style

Citing Format

MLA

Bikdeli B, et al.. "Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial." Thrombosis and Haemostasis, vol. 122, no. 1, 2021, pp. 131-141.

APA

Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Rezaeifar P, Baghizadeh E, Matin S, Jamalkhani S, Tahamtan O, Sharifkashani B, Beigmohammadi MT, Farrokhpour M, Sezavar SH, Payandemehr P, Dabbagh A, Moghadam KG, Khalili H, Yadollahzadeh M, ... Sadeghipour P (2021). Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial. Thrombosis and Haemostasis, 122(1), 131-141.

Chicago

Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Rezaeifar P, Baghizadeh E, et al.. "Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial." Thrombosis and Haemostasis 122, no. 1 (2021): 131-141.

Harvard

Bikdeli B et al. (2021) 'Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial', Thrombosis and Haemostasis, 122(1), pp. 131-141.

Vancouver

Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Rezaeifar P, et al.. Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial. Thrombosis and Haemostasis. 2021;122(1):131-141.

BibTex

@article{ author = {Bikdeli B and Talasaz AH and Rashidi F and Bakhshandeh H and Rafiee F and Rezaeifar P and Baghizadeh E and Matin S and Jamalkhani S and Tahamtan O and Sharifkashani B and Beigmohammadi MT and Farrokhpour M and Sezavar SH and Payandemehr P and Dabbagh A and Moghadam KG and Khalili H and Yadollahzadeh M and Riahi T and Abedini A and Lookzadeh S and Rahmani H and Zoghi E and Mohammadi K and Sadeghipour P and Abri H and Tabrizi S and Mousavian SM and Shahmirzaei S and Amin A and Mohebbi B and Parhizgar SE and Aliannejad R and Eslami V and Kashefizadeh A and Dobesh PP and Kakavand H and Hosseini SH and Shafaghi S and Ghazi SF and Najafi A and Jimenez D and Gupta A and Madhavan MV and Sethi SS and Parikh SA and Monreal M and Hadavand N and Hajighasemi A and Maleki M and Sadeghian S and Piazza G and Kirtane AJ and Van Tassell BW and Stone GW and Lip GYH and Krumholz HM and Goldhaber SZ and Sadeghipour P}, title = {Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial}, journal = {Thrombosis and Haemostasis}, volume = {122}, number = {1}, pages = {131-141}, year = {2021} }

RIS

TY - JOUR
AU - Bikdeli B
AU - Talasaz AH
AU - Rashidi F
AU - Bakhshandeh H
AU - Rafiee F
AU - Rezaeifar P
AU - Baghizadeh E
AU - Matin S
AU - Jamalkhani S
AU - Tahamtan O
AU - Sharifkashani B
AU - Beigmohammadi MT
AU - Farrokhpour M
AU - Sezavar SH
AU - Payandemehr P
AU - Dabbagh A
AU - Moghadam KG
AU - Khalili H
AU - Yadollahzadeh M
AU - Riahi T
AU - Abedini A
AU - Lookzadeh S
AU - Rahmani H
AU - Zoghi E
AU - Mohammadi K
AU - Sadeghipour P
AU - Abri H
AU - Tabrizi S
AU - Mousavian SM
AU - Shahmirzaei S
AU - Amin A
AU - Mohebbi B
AU - Parhizgar SE
AU - Aliannejad R
AU - Eslami V
AU - Kashefizadeh A
AU - Dobesh PP
AU - Kakavand H
AU - Hosseini SH
AU - Shafaghi S
AU - Ghazi SF
AU - Najafi A
AU - Jimenez D
AU - Gupta A
AU - Madhavan MV
AU - Sethi SS
AU - Parikh SA
AU - Monreal M
AU - Hadavand N
AU - Hajighasemi A
AU - Maleki M
AU - Sadeghian S
AU - Piazza G
AU - Kirtane AJ
AU - Van Tassell BW
AU - Stone GW
AU - Lip GYH
AU - Krumholz HM
AU - Goldhaber SZ
AU - Sadeghipour P
TI - Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial
JO - Thrombosis and Haemostasis
VL - 122
IS - 1
SP - 131
EP - 141
PY - 2021
ER -

Science Communicator Platform

Authors

Abstract